Expression of Axonal Transport Proteins in Dopaminergic Neurons of the Substantia Nigra in Mouse Models of Preclinical and Clinical Stages of Parkinson’s Disease
International Journal of Molecular Sciences · 2026
DOI: 10.3390/ijms27114895 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Anna Kolacheva und 8 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Neural and Neuroendocrine Regulations, Koltzov Institute of Developmental Biology, Russian Academy of Sciences, 26 Vavilova Street, 119…. Hauptthemen laut MEDLINE: Substantia Nigra, Axonal Transport, Dopaminergic Neurons, Parkinson Disease. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Russian Science Foundation.
Abstract (Originalsprache)
Impairment of axonal transport may contribute to the degeneration of dopaminergic (DAergic) neurons in the substantia nigra (SN), a key event in Parkinson’s disease (PD) pathogenesis. Due to the lack of early diagnosis, changes in axonal transport at the preclinical stage can only be studied in PD models. We assessed gene expression (RT-PCR after cell sorting) and protein levels (semiquantitative immunohistochemistry) of axonal transport-related proteins in SN DAergic neurons from mice in subchronic MPTP models of PD (preclinical and clinical stages) and controls. The proteins studied included α-tubulin (Tuba1a), β-tubulin (Tubb3), kinesin (Kif5b, Klc1), dynein (Dynll1, Dync1i1), dynactin (Dctn1), microtubule affinity-regulating kinase 1 (Mark1), and tau (Mapt). In the preclinical stage, Kif5b expression and Kif5B level were increased, possibly to compensatorily preserve anterograde transport. Dynll1 and Tuba1a were upregulated, whereas Dync1i1 and Mapt were downregulated, with no change in tubulin or tau protein levels. In the clinical stage, Klc1, Dync1i1, Dctn1, Mark1, and Mapt expression and Kif5B protein levels decreased. These data indicate that transcriptional alterations in axonal transport proteins precede protein-level changes in DAergic neurons. The upregulation of Kif5B in the preclinical stage suggests that axonal transport proteins may serve as potential early therapeutic targets in PD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Neural and Neuroendocrine Regulations, Koltzov Institute of Developmental Biology, Russian Academy of Sciences, 26 Vavilova Street, 119334 Moscow, Russia.
- The Institute of Digital Biodesign and Artificial Intelligence in Medicine, I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation, 8-2 Trubetskaya Street, 119991 Moscow,…
ORCID-Profile: Dmitry Troshev, Ekaterina Pavlova, Vsevolod Bogdanov, Maria Shchepina
Förderung
- Russian Science Foundation
Zitieren
APA
Kolacheva, A., Troshev, D., Antonova, A., Pavlova, E., Bogdanov, V., Kalashnikova, V., Popova, A., Shchepina, M., & Ugrumov, M. (2026). Expression of Axonal Transport Proteins in Dopaminergic Neurons of the Substantia Nigra in Mouse Models of Preclinical and Clinical Stages of Parkinson’s Disease. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27114895
Vancouver
Kolacheva A, Troshev D, Antonova A, Pavlova E, Bogdanov V, Kalashnikova V, et al. Expression of Axonal Transport Proteins in Dopaminergic Neurons of the Substantia Nigra in Mouse Models of Preclinical and Clinical Stages of Parkinson’s Disease. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27114895
BibTeX
@article{Kolacheva2026,
author = {Kolacheva, Anna and Troshev, Dmitry and Antonova, Alyona and Pavlova, Ekaterina and Bogdanov, Vsevolod and Kalashnikova, Varvara and Popova, Anna and Shchepina, Maria and Ugrumov, Michael},
title = {Expression of Axonal Transport Proteins in Dopaminergic Neurons of the Substantia Nigra in Mouse Models of Preclinical and Clinical Stages of Parkinson’s Disease},
journal = {International Journal of Molecular Sciences},
year = {2026},
doi = {10.3390/ijms27114895}
}
EUVIMED